Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Munich, Germany – 28 Aug 2018: Results of the first randomised trial testing the criteria used to diagnose heart attack are presented today in a Hot Line Session at ESC Congress 20181 and published in The Lancet².
Professor Nicholas Mills, principal investigator, University of Edinburgh, UK, said: “These results are controversial because they suggest that the Universal Definition of Myocardial Infarction needs to move away from binary thresholds to diagnose and treat patients with myocardial infarction. It is now up to the research community to find a superior approach.”
Myocardial infarction is one of the leading causes of death worldwide. It is diagnosed with a combination of clinical history, electrocardiogram and a rise or fall in the concentration of cardiac troponin,3,4 a protein released into the blood when the heart muscle is injured. The Universal Definition of Myocardial Infarction recommends that any increase in troponin above the 99th centile of a healthy reference population should be used as one of the diagnostic criteria.3,4
The High-STEACS trial5 is the first randomised trial to evaluate whether the introduction of a high-sensitivity cardiac troponin I assay with a 99th centile diagnostic threshold would reduce subsequent myocardial infarction or cardiovascular death at one year in patients with suspected acute coronary syndrome.
The trial included all patients presenting with suspected acute coronary syndrome to the emergency department at ten hospitals in Scotland, UK. All patients had measurements of cardiac troponin I using a contemporary assay as the standard of care and a high-sensitivity assay at presentation and six or 12 hours afterwards. During a six-month validation phase, clinical decisions were guided by the contemporary cardiac troponin I assay using the existing diagnostic threshold. Hospitals were then randomly allocated to early or late implementation of the high-sensitivity assay to guide clinical decisions using the 99th centile. Registries were used to record the primary outcome of myocardial infarction or cardiovascular death at one year.
The rate of the primary outcome was compared in patients reclassified using the high-sensitivity assay (above the 99th centile but below the contemporary assay threshold) before and after implementation of the high-sensitivity assay for clinical decision making.
A total of 48,282 patients were enrolled. The average age was 61 years and 47% were women. Just over one-fifth (10,360; 22%) had high-sensitivity cardiac troponin I concentrations above the 99th centile. The high-sensitivity assay reclassified 1,771 (17%) patients with myocardial injury or infarction not identified by the standard assay. Of those, less than one third had a final diagnosis of myocardial infarction.
In those reclassified, the primary outcome occurred in 105 of 720 (14.6%) patients in the validation phase and 131 of 1,051 (12.5%) patients in the implementation phase. The adjusted odds ratio for the implementation versus validation phase was 1.10 (95% confidence interval 0.75–1.61, p=0.620).
Professor Mills said: “The trial found that implementation of a high-sensitivity cardiac troponin I assay using the 99th centile as the diagnostic threshold increased the frequency of diagnosing myocardial injury or infarction. However, use of this method to help diagnose and treat patients was not associated with lower rates of recurrent myocardial infarction or cardiovascular death at one year.”
He continued: “The findings were surprising and initially disappointing. But it was encouraging that there was no evidence of misdiagnosis, inappropriate treatment, excess bleeding or harm. Indeed, the length of stay across the trial population was reduced by almost a third suggesting that use of the high-sensitivity test increased the confidence of clinicians to rule out heart disease, with benefits for health service providers.”
Professor Mills noted that the trial was embedded within routine clinical assessment with hospitals as the unit of randomisation. “It included every patient evaluated using the test, thereby avoiding selection bias and ensuring that the findings are generalisable,” he said.
1 High-STEACS will be discussed during:
² The Lancet : http://dx.doi.org/10.1016/S0140-6736(18)31923-8
3 Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551–2567. doi: 10.1093/eurheartj/ehs184.
4 2018 ESC/ACCF/AHA/WHF Fourth Universal Definition of Myocardial Infarction. European Heart Journal. 2018. doi: 10.1093/eurheartj/ehy462.
5 High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary Syndrome (High-STEACS).
SOURCES OF FUNDING: This trial was funded by the British Heart Foundation. Abbott Laboratories provided cardiac troponin assay reagents, calibrators, and controls without charge.
DISCLOSURES: Anoop S.V. Shah and Andrew R. Chapman have received honoraria from Abbott Diagnostics. Nicholas L. Mills has received honoraria and consultancy from Abbott Diagnostics, Roche Diagnostics and Singulex.
TWITTER handle: @highSTEACS
ESC Press OfficeFor press enquiries, independent comment on-site, please contact the ESC Press Office at firstname.lastname@example.org
To access congress scientific resources visit ESC Congress 365.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2018
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2018. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease.
© 2019 European Society of Cardiology. All rights reserved.